Table 3. Exploratory Outcomes Representing Health-Related Quality of Life.

Exploratory outcomes	Patients with measurement				Between-group difference
	Pamrevlumab (n = 181)		Placebo (n = 175)		Absolute difference (95% CI)	P value
	No. (%)	Change in outcome, least-squares mean (SD)	No (%)	Change in outcome, least-squares mean (SD)
Quantitative lung fibrosis volume, mLa	157 (86.7)	251.4 (478.14)	143 (81.7)	268.0 (465.87)	−16.58 (−103.21 to 70.05)	.71
St George’s Respiratory Questionnaire scoreb	153 (84.5)	11.3 (25.47)	133 (76.0)	12.1 (24.86)	−0.72 (−5.44 to 3.99)	.76
University of California San Diego–Shortness of Breath Questionnaire scorec	147 (81.2)	19.6 (34.51)	129 (73.7)	20.5 (34.00)	−0.91 (−7.40 to 5.59)	.78
Leicester Cough Questionnaire scored	154 (85.1)	−2.4 (6.00)	137 (78.3)	−2.7 (5.78)	0.36 (−0.73 to 1.46)	.52

^a This computer-assisted quantitative scoring system measures the degree and progression of lung fibrosis viewed by high-resolution computed tomography. Volumes range from 0 mL to maximum lung volume; greater volumes represent increased fibrosis.

^b The score range is from 0 to 100; lower scores indicate better health and fewer symptoms. A score between 25 and 50 indicates moderate impairment. A score greater than 50 indicates severe impairment in health-related quality of life and the ability to complete activities of daily living.

^c The score range is from 0 to 120; lower scores indicate lower severity of shortness of breath. A score between 20 and 60 indicates moderate shortness of breath. A score of 60 or greater indicates severe shortness of breath that would have an effect on daily living and health-related quality of life.

^d The score range is from 3 to 21; lower scores indicate greater health impairment due to cough. A score between 14 and 17 indicates moderate impairment due to cough. A score greater than 17 indicates severe impairment that would have an effect on daily living and health-related quality of life.